News | March 21, 2022
Lonza signs manufacturing agreement with Oasmia Pharmaceutical
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
It is only the second generic application approved by the USFDA
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC)
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Subscribe To Our Newsletter & Stay Updated
